| Dr Zachary Ian Abbott, DO | |
|
3901 Capital Mall Dr Sw, Ste A, Olympia, WA 98502-8654 | |
| (360) 786-8990 | |
| (360) 786-9010 |
| Full Name | Dr Zachary Ian Abbott |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 20 Years |
| Location | 3901 Capital Mall Dr Sw, Olympia, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154445203 | NPI | - | NPPES |
| 8537953 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | OP60077457 (Washington) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | OP60077457 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olympia Orthopaedic Associates, Pllc | 2365337508 | 79 |
News Archive
Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.
Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
Early in the tumultuous 2020-21 school year, Missouri officials made a big gamble: set aside roughly 1 million rapid covid tests for the state's K-12 schools in hopes of quickly identifying sick students or staff members.
Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
With cardiovascular disease (CVD) causing a third of all deaths in Australia, NPS MedicineWise is encouraging GPs to stay up to date with their knowledge about CVD risk assessment and therapy.
› Verified 4 days ago
| Entity Name | Olympia Orthopaedic Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083785398 PECOS PAC ID: 2365337508 Enrollment ID: O20040217001032 |
News Archive
Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.
Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
Early in the tumultuous 2020-21 school year, Missouri officials made a big gamble: set aside roughly 1 million rapid covid tests for the state's K-12 schools in hopes of quickly identifying sick students or staff members.
Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
With cardiovascular disease (CVD) causing a third of all deaths in Australia, NPS MedicineWise is encouraging GPs to stay up to date with their knowledge about CVD risk assessment and therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zachary Ian Abbott, DO Po Box 368, Olympia, WA 98507-0368 Ph: (360) 455-5144 | Dr Zachary Ian Abbott, DO 3901 Capital Mall Dr Sw, Ste A, Olympia, WA 98502-8654 Ph: (360) 786-8990 |
News Archive
Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.
Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
Early in the tumultuous 2020-21 school year, Missouri officials made a big gamble: set aside roughly 1 million rapid covid tests for the state's K-12 schools in hopes of quickly identifying sick students or staff members.
Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
With cardiovascular disease (CVD) causing a third of all deaths in Australia, NPS MedicineWise is encouraging GPs to stay up to date with their knowledge about CVD risk assessment and therapy.
› Verified 4 days ago